A Phase 1/2 Multi-center Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Subjects With Refractory Large B-Cell Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 26 Dec 2018
At a glance
- Drugs Axicabtagene ciloleucel (Primary) ; Utomilumab (Primary) ; Cyclophosphamide; Fludarabine
- Indications B-cell lymphoma; Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms ZUMA-11
- Sponsors Kite Pharma
- 30 Nov 2018 Status changed from not yet recruiting to recruiting.
- 10 Oct 2018 Status changed from planning to not yet recruiting.
- 22 Jan 2018 New trial record